Jia Luo, MD

home / authors / jia-luo-md

Articles

Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.

Divarasib Combo Appears “Promising” in Pretreated KRAS G12C+ NSCLC

Jia Luo, MD
May 5th 2025

Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.

Face-Off: Award Presentations and Event Conclusion

Face-Off: Award Presentations and Event Conclusion

Jia Luo, MD;Narjust Florez, MD;Justin Gainor, MD;Scott J. Swanson, MD;Anne Chiang, MD ;Roy S. Herbst, MD, PhD;So Yeon Kim, MD;Justin Blasberg, MD, MPH, FACS
January 4th 2024

Judy concludes the event and presents the awards.

Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic NSCLC

Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic NSCLC

Jia Luo, MD;Narjust Florez, MD;Justin Gainor, MD;Scott J. Swanson, MD;Anne Chiang, MD ;Roy S. Herbst, MD, PhD;So Yeon Kim, MD;Justin Blasberg, MD, MPH, FACS
January 4th 2024

A debate presented on liquid biopsy versus tissue biopsy to determine front line therapy in metastatic NSCLC.

Association Between Medicaid Insurance, Biomarker Testing, and Outcomes in Patients With Advanced NSCLC

Association Between Medicaid Insurance, Biomarker Testing, and Outcomes in Patients With Advanced NSCLC

Jia Luo, MD;Narjust Florez, MD;Justin Gainor, MD;Scott J. Swanson, MD;Anne Chiang, MD ;Roy S. Herbst, MD, PhD;So Yeon Kim, MD;Justin Blasberg, MD, MPH, FACS
December 28th 2023

Dr. Florez leads the discussion on the association between Medicaid insurance, biomarker testing, and the outcomes in patients with advanced NSCLC.

Amivantamab in EGFR Exon 20 Insertion Mutated NSCLC Progression on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase 1 Study

Amivantamab in EGFR Exon 20 Insertion Mutated NSCLC Progression on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase 1 Study

Jia Luo, MD;Narjust Florez, MD;Justin Gainor, MD;Scott J. Swanson, MD;Anne Chiang, MD ;Roy S. Herbst, MD, PhD;So Yeon Kim, MD;Justin Blasberg, MD, MPH, FACS
December 28th 2023

Dr. Herbst discusses the CHRYSALIS Phase 1 trial.

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA NSCLC: Updated Results From the Phase III Randomized ADAURA Trial

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA NSCLC: Updated Results From the Phase III Randomized ADAURA Trial

Jia Luo, MD;Narjust Florez, MD;Justin Gainor, MD;Scott J. Swanson, MD;Anne Chiang, MD ;Roy S. Herbst, MD, PhD;So Yeon Kim, MD;Justin Blasberg, MD, MPH, FACS
December 21st 2023

An overview of results from the phase III randomized ADAURA Trial.

Brigatinib Versus Crizotinib in ALK Inhibitor-Naïve Advanced ALK-Positive NSCLC: Results on Phase 3 ALTA-1L Trial

Brigatinib Versus Crizotinib in ALK Inhibitor-Naïve Advanced ALK-Positive NSCLC: Results on Phase 3 ALTA-1L Trial

Jia Luo, MD;Narjust Florez, MD;Justin Gainor, MD;Scott J. Swanson, MD;Anne Chiang, MD ;Roy S. Herbst, MD, PhD;So Yeon Kim, MD;Justin Blasberg, MD, MPH, FACS
December 21st 2023

A review of Brigatinib versus crizotinib in ALK inhibitor-naïve advanced ALK-positive NSCLC.

KRYSTAL-1: Two Year Follow Up of Adagrasib Monotherapy in Patients With Advanced/Metastatic KRAS G12C Mutated NSCLC

KRYSTAL-1: Two Year Follow Up of Adagrasib Monotherapy in Patients With Advanced/Metastatic KRAS G12C Mutated NSCLC

Jia Luo, MD;Narjust Florez, MD;Justin Gainor, MD;Scott J. Swanson, MD;Anne Chiang, MD ;Roy S. Herbst, MD, PhD;So Yeon Kim, MD;Justin Blasberg, MD, MPH, FACS
December 14th 2023

A review of adagrasib in the KRYSTAL-1 trial in patients with NSCLC.

Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients with ALK Positive Advanced NSCLC from the Phase III CROWN Study

Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients with ALK Positive Advanced NSCLC from the Phase III CROWN Study

Jia Luo, MD;Narjust Florez, MD;Justin Gainor, MD;Scott J. Swanson, MD;Anne Chiang, MD ;Roy S. Herbst, MD, PhD;So Yeon Kim, MD;Justin Blasberg, MD, MPH, FACS
December 14th 2023

A discussion on the Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients with ALK Positive Advanced NSCLC: Phase III CROWN Study

Long Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients with Pretreated KRAS G12C-Mutated NSCLC

Long Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients with Pretreated KRAS G12C-Mutated NSCLC

Jia Luo, MD;Narjust Florez, MD;Justin Gainor, MD;Scott J. Swanson, MD;Anne Chiang, MD ;Roy S. Herbst, MD, PhD;So Yeon Kim, MD;Justin Blasberg, MD, MPH, FACS
December 7th 2023

The outcomes of the use of Sotorasib in patients with pretreated KRAS G12C mutated NSCLC.

Face-Off: Introduction of the Non-Small Lung Cancer (NSCLC) Debate

Face-Off: Introduction of the Non-Small Lung Cancer (NSCLC) Debate

Jia Luo, MD;Narjust Florez, MD;Justin Gainor, MD;Scott J. Swanson, MD;Anne Chiang, MD ;Roy S. Herbst, MD, PhD;So Yeon Kim, MD;Justin Blasberg, MD, MPH, FACS
December 7th 2023

Highlight on the debate format, speakers, and direction to support the discussion.

Site Logo

Treatment of Nonmetastatic Castration-Resistant Prostate Cancer

Jia Luo, MD;Tomasz M. Beer, MD;Julie N. Graff, MD
April 16th 2016

Here we review current therapies for nonmetastatic CRPC and discuss the recently completed and ongoing trials for this emerging disease state.

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Published: January 24th 2025 | Updated: February 6th 2025
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
A 23-Year-Old Male With Right Leg Pain
Published: April 26th 2018 | Updated: July 25th 2025
A 23-Year-Old Male With Right Leg Pain